Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Crossing over01:34

Crossing over

Unlike mitosis, meiosis aims for genetic diversity in its creation of haploid gametes. Dividing germ cells first begin this process in prophase I, where each chromosome—replicated in S phase—is now composed of two sister chromatids (identical copies) joined centrally.
The homologous pairs of sister chromosomes—one from the maternal and one from the paternal genome—then begin to align alongside each other lengthwise, matching corresponding DNA positions in a process called synapsis.
In order to...
Crossing Over01:30

Crossing Over

Crossing over is the exchange of genetic information between homologous chromosomes during prophase I of meiosis I. Genetic recombination gives rise to allelic diversity in the newly formed daughter cells. In humans, crossing over produces genetically distinct haploid egg and sperm cells that undergo fertilization to produce unique offspring. Before cell division starts, the germ cell’s chromosome(s) undergo duplication in the S phase of the cell cycle. As the cells enter prophase I, duplicated...
Crossing Over01:34

Crossing Over

Unlike mitosis, meiosis aims for genetic diversity in its creation of haploid gametes. Dividing germ cells first begin this process in prophase I, where each chromosome—replicated in S phase—is now composed of two sister chromatids (identical copies) joined centrally.
The homologous pairs of sister chromosomes—one from the maternal and one from the paternal genome—then begin to align alongside each other lengthwise, matching corresponding DNA positions in a process called synapsis.
In order to...
Hydraulic Jump: Problem Solving01:16

Hydraulic Jump: Problem Solving

To analyze a hydraulic jump in a rectangular channel with a flow speed of 6 meters per second, follow these steps:Calculate Effective Upstream Velocity:When the downstream gate closes, a hydraulic jump forms, traveling upstream at 2 meters per second. This wave speed combines with the initial channel flow velocity, creating an effective upstream velocity.Identify Flow Velocities Before and After the Hydraulic Jump:Upstream of the hydraulic jump, the effective flow velocity includes both the...
Test Cross01:39

Test Cross

Alleles are different forms of the same gene. Humans and other diploid organisms inherit two alleles of every gene, one from each parent.
Test Cross01:39

Test Cross

Alleles are different forms of the same gene. Humans and other diploid organisms inherit two alleles of every gene, one from each parent.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The UK's Life Sciences Strategy: opportunities for clinical pharmacology.

British journal of clinical pharmacology·2018
Same author

Cost, Effectiveness, and Value: How to Judge?

JAMA·2016
Same author

Incidence of adult Huntington's disease in the UK: a UK-based primary care study and a systematic review.

BMJ open·2016
Same author

The Prevalence of Huntington's Disease.

Neuroepidemiology·2016
Same author

National Institute for Clinical Excellence: NICE works.

Journal of the Royal Society of Medicine·2015
Same author

Author's reply to Poole, Conway, Bewley, Sundar, and Chalmers and Firkins.

BMJ (Clinical research ed.)·2014

Related Experiment Video

Updated: May 24, 2026

Systematic Bronchoscopy: the Four Landmarks Approach
04:47

Systematic Bronchoscopy: the Four Landmarks Approach

Published on: June 23, 2023

Crossing the fourth hurdle.

Michael D Rawlins1

  • 1National Institute for Health and Clinical Excellence, 71 High Holborn, London WC1V 6NA, UK. michael.rawlins@nice.org.uk

British Journal of Clinical Pharmacology
|March 13, 2012
PubMed
Summary
This summary is machine-generated.

Pharmaceutical companies must prove new drugs offer good value, not just quality, effectiveness, and safety. Demonstrating superior benefits over cost and considering societal values are crucial for healthcare system approval.

More Related Videos

A Training Program Using an Agility Ladder for Community-Dwelling Older Adults
14:13

A Training Program Using an Agility Ladder for Community-Dwelling Older Adults

Published on: March 7, 2020

Using a Virtual Reality Walking Simulator to Investigate Pedestrian Behavior
06:38

Using a Virtual Reality Walking Simulator to Investigate Pedestrian Behavior

Published on: June 9, 2020

Related Experiment Videos

Last Updated: May 24, 2026

Systematic Bronchoscopy: the Four Landmarks Approach
04:47

Systematic Bronchoscopy: the Four Landmarks Approach

Published on: June 23, 2023

A Training Program Using an Agility Ladder for Community-Dwelling Older Adults
14:13

A Training Program Using an Agility Ladder for Community-Dwelling Older Adults

Published on: March 7, 2020

Using a Virtual Reality Walking Simulator to Investigate Pedestrian Behavior
06:38

Using a Virtual Reality Walking Simulator to Investigate Pedestrian Behavior

Published on: June 9, 2020

Area of Science:

  • Health economics
  • Pharmaceutical policy
  • Health services research

Background:

  • Healthcare systems increasingly require pharmaceutical manufacturers to demonstrate value for money.
  • New drug approvals necessitate evidence of quality, efficacy, safety, and cost-effectiveness.
  • The 'fourth hurdle' in drug approval focuses on economic and societal value.

Purpose of the Study:

  • To analyze the requirements for pharmaceutical manufacturers to overcome the 'fourth hurdle' in healthcare system approvals.
  • To examine the criteria used by decision-makers in evaluating new pharmaceutical products.
  • To highlight the importance of balancing scientific evidence with social values in drug approval processes.

Main Methods:

  • Review of current healthcare system requirements for pharmaceutical product approval.
  • Analysis of economic and clinical data evaluation frameworks.
  • Examination of the role of societal values in health technology assessment.

Main Results:

  • Pharmaceutical manufacturers must provide robust evidence of enhanced benefits relative to cost compared to existing treatments.
  • Demonstrating cost-effectiveness alongside quality, efficacy, and safety is a critical requirement.
  • Decision-making processes integrate scientific data with the social values of the population served.

Conclusions:

  • Successfully navigating the 'fourth hurdle' requires a comprehensive approach combining scientific rigor with economic and social considerations.
  • Pharmaceutical companies need to present compelling value propositions that resonate with both scientific and societal expectations.
  • Effective drug approval policies necessitate a nuanced understanding of value that extends beyond purely clinical metrics.